RAD1

Cell cycle checkpoint protein RAD1

911 patent compounds predicted against RAD1, 618 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15758872	1.00	2/20
SCHEMBL29352177	1.00	2/20
SCHEMBL17208336	0.78	2/20
SCHEMBL15758657	0.78	2/20
SCHEMBL15758185	0.76	2/20
SCHEMBL15758931	0.76	2/20
SCHEMBL15758474	0.75	2/20
SCHEMBL17202955	0.75	2/20
SCHEMBL15758183	0.74	2/20
SCHEMBL17201949	0.74	2/20
SCHEMBL15758221	0.72	2/20
SCHEMBL15758589	0.67	2/20
SCHEMBL15758430	0.67	2/20
SCHEMBL15758482	0.65	2/20
SCHEMBL15758591	0.61	2/20
SCHEMBL17208335	0.58	2/20
SCHEMBL15757958	0.46	2/20
SCHEMBL15758402	0.45	2/20
SCHEMBL15758540	0.44	2/20
SCHEMBL15758335	0.43	2/20

Germline variants in RAD1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full RAD1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to RAD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma	PHASE1/PHASE2	COMPLETED
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations	PHASE2	RECRUITING
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer	PHASE2	WITHDRAWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)	PHASE1/PHASE2	UNKNOWN
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer	PHASE1/PHASE2	COMPLETED
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer	PHASE1	WITHDRAWN
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RAD1 binder may also engage these)

Protein	Name	Similarity
Q5R7X9	—	1.000	Q5R7X9 →
Q9QWZ1	—	1.000	Q9QWZ1 →
Q8BQY8	—	0.966	Q8BQY8 →
O60921	—	0.963	O60921 →
A6QNS3	—	0.921	A6QNS3 →
O82797	—	0.920	O82797 →
A0A0G2JTR4	—	0.920	A0A0G2JTR4 →
Q5SSL4	—	0.917	Q5SSL4 →
Q9ESN6	—	0.912	Q9ESN6 →
D3ZQG6	—	0.912	D3ZQG6 →
Q8AVG0	—	0.912	Q8AVG0 →
Q9M7Q7	—	0.911	Q9M7Q7 →
Q6NVC5	—	0.911	Q6NVC5 →
A4II46	—	0.910	A4II46 →
P24314	—	0.910	P24314 →
Q8BG51	—	0.909	Q8BG51 →
Q12979	—	0.909	Q12979 →
Q8IWZ6	—	0.909	Q8IWZ6 →
Q43124	—	0.908	Q43124 →
Q43266	—	0.908	Q43266 →
O54956	—	0.908	O54956 →
Q96JC1	—	0.908	Q96JC1 →
D2GXS7	—	0.908	D2GXS7 →
Q5U2Y3	—	0.908	Q5U2Y3 →
Q5T2T1	—	0.907	Q5T2T1 →
Q8R5L3	—	0.907	Q8R5L3 →
Q8K2G4	—	0.906	Q8K2G4 →
Q9WUV0	—	0.906	Q9WUV0 →
A6QQZ7	—	0.906	A6QQZ7 →
A1L1L6	—	0.906	A1L1L6 →